Engineered T Cell Expression for Tumor-Site Immunomodulator Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
CAR T cells face limitations in treating solid cancers due to tumor heterogeneity, inefficient trafficking, and immunosuppressive mechanisms in the tumor microenvironment, with previous attempts at enhancing their efficacy leading to severe toxicities from uncontrolled immunomodulatory factor expression.
Innovation Solution
Engineered T cells with a heterologous nucleotide sequence encoding immunomodulatory factors are introduced in-frame within endogenous genes under the control of tumor-specific regulatory elements, allowing controlled, tumor-site-specific expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunomodulatory factors are constitutively expressed in CAR T cells to enhance therapeutic efficacy, then anti-tumor activity is improved, but severe toxicities occur including liver dysfunction, high fevers and hemodynamic instability
Solution Approach 1:
The patent applies dynamics by making the expression of immunomodulatory factors conditional and inducible rather than constitutive. The T cells contain latent genetic circuits that remain dormant until activated by specific tumor-associated antigens or microenvironmental cues, allowing the system to adapt its immunomodulatory output dynamically based on tumor presence and tissue location, thereby achieving therapeutic efficacy while avoiding systemic toxicity
Solution Approach 2:
The patent implements local quality by enabling spatially restricted expression of immunomodulatory factors specifically at the tumor site. Through tissue-specific promoters, conditional activation systems, and targeted delivery mechanisms, the immunomodulatory activity is confined to the tumor microenvironment rather than being distributed systemically, thus treating the cancer while sparing healthy organs from toxic effects
2Adaptability or versatility
If CAR T cells are engineered to express immunomodulatory factors to overcome tumor heterogeneity and immunosuppression, then widespread effects on endogenous immune mechanisms are achieved, but uncontrolled transgene expression leads to life-threatening toxicities
Solution Approach 1:
The patent applies preliminary action by pre-equipping T cells with integrated genetic circuits containing immunomodulatory factor genes under the control of inducible promoters before adoptive transfer. These circuits are designed with built-in safety switches and regulatory elements that prevent premature expression, allowing the cells to be prepared in advance and then activated only when they encounter the appropriate tumor-specific signals in vivo
Solution Approach 2:
The patent implements feedback mechanisms through inducible expression systems that respond to tumor-specific antigens, microenvironmental cues, or artificial induction signals. The expression of immunomodulatory factors is tightly coupled to the presence of target antigens or specific activation conditions, creating a feedback loop where the system automatically regulates its own output based on real-time tumor presence and tissue context, ensuring adaptability while maintaining expression control
Data Source
AI summary
The present disclosure relates generally to T cells, e.g., CAR T cells, which have been engineered to express immunomodulatory factors in a tumor-site specific manner. The engineered T cells and pharmaceutical compositions comprising the engineered T cells exhibit improved therapeutic efficacy and reduced toxicity when used for the treatment of cancer. In other embodiments contemplated herein, the present disclosure relates to genome editing systems for engineering T cells to express immunomodulatory factors in a tumor-site specific manner.